Cochrane Abstracts
Tocilizumab for thyroid eye disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Tocilizumab for Thyroid Eye Disease." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/435139/all/Tocilizumab_for_thyroid_eye_disease.
Tocilizumab for thyroid eye disease. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435139/all/Tocilizumab_for_thyroid_eye_disease. Accessed December 7, 2024.
Tocilizumab for thyroid eye disease. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/435139/all/Tocilizumab_for_thyroid_eye_disease
Tocilizumab for Thyroid Eye Disease [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 07]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/435139/all/Tocilizumab_for_thyroid_eye_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Tocilizumab for thyroid eye disease
ID - 435139
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/435139/all/Tocilizumab_for_thyroid_eye_disease
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
